The paradigm set by TKI (Tyrosine kinase inhibitors) therapy of CML (Chronic myelo id leukemia) and ALK inhibition (Anaplastic lymphoma kinase) in a small subset of patients with non-small cell lung cancer is quite compelling. The gene discussed is ALK; the disease is non-small cell lung carcinoma.